Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399.
about
(125)I Seed Permanent Implantation as a Palliative Treatment for Stage III and IV Hypopharyngeal CarcinomaFunctional outcomes after chemoradiotherapy of laryngeal and pharyngeal cancersPreservation of organ function in head and neck cancer.Transoral laser microsurgery (TLM) +/- adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors.Assessing feasibility, compliance and toxicity of concomitant chemo-radiotherapy in head and neck cancers in the Northern Territory: initial experience and challenges.Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study.Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer.Swallowing function after transoral laser microsurgery (TLM) ± adjuvant therapy for advanced-stage oropharyngeal cancer.Surgical management of T1 oropharyngeal carcinoma.A head and neck cancer tumor response-specific gene signature for cisplatin, 5-fluorouracil induction chemotherapy fails with added taxanesEpstein-Barr virus and human papillomavirus infections and genotype distribution in head and neck cancersImproved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.Recent advances in combined modality therapyInduction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective studyA phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.Transoral laser microsurgery for oropharyngeal squamous cell carcinoma: A paradigm shift in therapeutic approach.Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy.Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors.Prognostic Value of FDG-PET in patients with oropharyngeal carcinoma treated with concurrent chemoradiotherapy.Integrating biologically targeted therapy in head and neck squamous cell carcinomasTreatment of head and neck cancers: issues for clinical pharmacists.A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer.Salvage surgery after locoregional failure in head and neck carcinoma patients treated with chemoradiotherapy.Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer.Current concepts of organ preservation in head and neck cancer.Volume-based trends in surgical care of patients with oropharyngeal cancer.Oral cancers: supportive care issues.Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: the Fox Chase Cancer Center experience.Emerging insights into head and neck cancer metastasis.Effectiveness of chemotherapy and radiotherapy for laryngeal preservation in advanced laryngeal cancer: a meta-analysis and systematic review.Comparison of the therapeutic effects of total laryngectomy and a larynx-preservation approach in patients with T4a laryngeal cancer and thyroid cartilage invasion: A multicenter retrospective review.Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cellGene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line.Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma.Squamous cell carcinoma of the oropharynx: single-institution outcome analysis of patients treated with concurrent chemoradiotherapy.Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.Persistent Tracheostomy after Organ Preservation Protocol in Patients Treated for Larynx and Hypopharynx Cancer.E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.Surgical techniques and treatment outcomes of transoral robotic supraglottic partial laryngectomy.
P2860
Q26738657-DB907ACD-0073-4A11-B8AB-691F5F77F8DCQ26866157-D8C2E3B4-4961-467A-9FFD-7166DA1B3BF4Q30459136-E7E524C1-35DE-4592-B19B-AE64D96E2FB0Q33477468-F8200108-D21D-43CC-983F-5FD016983746Q33753722-F6EBAEBE-411E-4057-929E-2BFC2D72C0DBQ33809636-C6D5AF75-24B0-4DCC-9815-1B170B28B172Q33886464-7720FC23-1CCB-4236-A4C3-7489371748A2Q34007100-3A928453-E04F-4377-A9DB-81FCAEE7BB46Q34074591-262AAF63-A4D4-4C64-9AA0-5F07FB00F5F0Q34442876-56F8A0A5-482B-4AF0-B3D0-4E629C750505Q34535924-05554678-5A7F-4416-A0B7-15FAF6D63A4CQ34749494-2C714EC9-430B-4983-9196-FB4A686306B7Q35152720-8152F6CF-782C-4C17-8D01-5F86E0E15EDBQ35584002-ED042771-1899-497F-BEC6-8F6E1BAB6BB9Q35605411-35925AF8-0A4F-4150-AFCC-91211182A07BQ35836433-FBB327BD-6ADB-4DD7-884D-3CA332B0A191Q35978949-5F9B7173-DC52-4681-850A-2D6B8DD6E496Q35989974-EACD6968-A5DE-4E0B-92AD-69071C56832AQ36116471-FD64A5E1-6025-4BB3-A33F-BD43F736F781Q36784797-165DBB56-1926-41DF-AEBD-07E09C13938CQ37081427-734576BF-A398-4A60-8F46-7FF092885AB4Q37461437-3C61E7E9-6251-42D1-8551-D2940258D303Q37586420-6E581D55-DD71-49E6-ACE3-8E2E5A7E7FAFQ37780973-492AC7A1-D7FB-4F7E-A305-1C118F04A969Q37799933-26C30DE3-E72C-4CA8-9659-43021DCA7009Q37812316-7887FE96-C2BD-4631-A675-FCBB2F1D99F7Q37851904-494469A2-F772-49BD-9D2A-A8000A577C4AQ37903909-A897E3E8-BA1D-45CC-8007-D159BE835B2CQ37934778-3469B4BC-780F-46F2-BD3C-4450178B794AQ38070999-6030E06C-355A-48CB-8AED-EA70CAC091A8Q38485149-083F71E2-3CD9-4CD9-BE88-2461030D8D1FQ38797651-2B400DB7-437E-4216-A7E5-B5C7B74EC777Q39051376-0C85BA8E-3DF4-44A3-BC10-FAAA59BF6257Q39130540-FB63DF3B-99B8-4537-A46F-3CA5AB2C6E94Q40046181-00691CBA-D227-4A1B-9109-486E20A61F28Q41367967-1F46D494-015A-4581-B1D1-B6AC18277762Q41681595-ACE367E5-6ADC-4199-845A-FF9492082C9DQ42277694-C768D5A7-BAFC-4B7C-AED6-0584E988047AQ43041829-7B20979E-5683-4F76-8CC6-1C66FF152BEFQ43460805-B91EA813-CB69-4BDB-889E-22F42CA8EA28
P2860
Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Phase II trial of chemoradiati ...... ve Oncology Group Study E2399.
@en
Phase II trial of chemoradiati ...... ve Oncology Group Study E2399.
@nl
type
label
Phase II trial of chemoradiati ...... ve Oncology Group Study E2399.
@en
Phase II trial of chemoradiati ...... ve Oncology Group Study E2399.
@nl
prefLabel
Phase II trial of chemoradiati ...... ve Oncology Group Study E2399.
@en
Phase II trial of chemoradiati ...... ve Oncology Group Study E2399.
@nl
P2093
P921
P356
P1476
Phase II trial of chemoradiati ...... ive Oncology Group Study E2399
@en
P2093
Anthony J Cmelak
Arlene A Forastiere
Barbara Murphy
Harlan Pinto
Maura Gillison
Meredith A Goldwasser
Michael Cannon
P304
P356
10.1200/JCO.2007.10.8951
P407
P577
2007-09-01T00:00:00Z